SOPHiA GENETICS SA
No enriched coverage for $SOPH in the last 7 days.
No SEC Form 4 filings for $SOPH in the last 30 days.
SOPHiA GENETICS' Chief Medical Officer, Philippe Menu, sold 5,000 Ordinary Shares at a weighted average price of $4.8178 per share under a pre-scheduled Rule 10b5-1(c) trading plan. This transaction represents approximately 2% of his holdings, leaving him with 261,388 Ordinary Shares. The sale was an open-market transaction with individual trades ranging from $4.75 to $4.89.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will release its financial results for the first quarter of 2026 before U.S. markets open on Tuesday, May 5, 2026. The company will also host a conference call on the same day at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the results and business outlook. A webcast of the call and a replay will be available on the SOPHiA GENETICS Investor Relations Website.
SOPHiA GENETICS' President, Ross Muken, recently sold 2,800 shares of SOPH stock for $13,888.00 as part of a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations. Despite this insider selling and the company missing recent EPS expectations with negative margins, analysts have raised price targets for SOPH, and a new collaboration with Mount Sinai is expected to drive platform adoption and revenue growth. Institutional investors have also slightly increased their holdings in the company.
